home / stock / inm / inm news

INM News and Press, InMed Pharmaceuticals Inc. From 05/24/23

Stock Information
Company Name: InMed Pharmaceuticals Inc.
Stock Symbol: INM
Market: NASDAQ
Website: inmedpharma.com
Menu
INM INM Quote INM Short INM News INM Articles INM Message Board
Get INM Alerts

News, Short Squeeze, Breakout and More Instantly...
INM - InMed to Participate in Upcoming Virtual Investor Events

Vancouver, British Columbia--(Newsfile Corp. - May 24, 2023) - InMed Pharmaceuticals Inc. ( NASQDAQ: INM ) (" InMed " or the " Company "), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announce that th...
INM - Lucy Scientific, Bioventus top healthcare gainers; Enveric, Elevation among losers

2023-05-19 10:04:48 ET Gainers: Lucy Scientific Discovery ( LSDI ) +51% . Bioventus ( BVS ) +44% . Mallinckrodt ( MNK ) +28% . 180 Life Sciences ( ATNF ) +28% . Stereotaxis ( STXS ) +25% . Losers: Enveric Biosciences ( ENVB ...

INM - InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ET

Vancouver, British Columbia--(Newsfile Corp. - May 18, 2023) - InMed Pharmaceuticals Inc. ( NASDAQ: INM ) (" InMed " or the " Company "), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announce Eric A. ...

INM - InMed Pharmaceuticals GAAP EPS of -$0.60, revenue of $1.03M

2023-05-15 17:20:16 ET InMed Pharmaceuticals press release ( NASDAQ: INM ): Q1 GAAP EPS of -$0.60. Revenue of $1.03M (+232.3% Y/Y). For further details see: InMed Pharmaceuticals GAAP EPS of -$0.60, revenue of $1.03M
INM - InvestorNewsBreaks - InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Q3 2023 Financial Results, Provides Business Update

InMed Pharmaceuticals (NASDAQ: INM) , a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced financial results for the third quarter of the fiscal year 2023, which ended March 31, 2023. “The th...

INM - InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

Completed enrollment in Phase 2 Clinical Trial; data readout expected during calendar 3Q 2023 120% quarter-over-quarter revenue growth in the commercial BayMedica subsidiary Published a peer-reviewed study showing the anti-inflammatory potential of rare cannabinoids Vancouver, British Co...

INM - InMed completes enrollment to test cannabinol cream to treat epidermolysis bullosa, results from trial in early Q3

2023-03-28 09:12:37 ET InMed Pharma ( NASDAQ: INM ) said it had completed enrollment for its Phase 2 trial testing investigational drug, INM-755, a cannabinol cream to treat epidermolysis bullosa (EB), a rare genetic skin disease. The company said results from the Phase 2 ...
INM - InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa

Marks the first time a Phase 2 trial has studied a cannabinol (CBN) formulation as a treatment option for any disease Data expected to be released in early calendar Q3 2023 Vancouver, British Columbia--(Newsfile Corp. - March 28, 2023) - InMed Pharmaceuticals Inc. ( NASDAQ: INM ) (" InMed "...

INM - LKCO, VIA and ADD among mid-day movers

2023-03-22 13:29:15 ET Gainers: GameStop ( GME ) +41% . Telesis Bio ( TBIO ) +31% . EZGO Technologies ( EZGO ) +33% . CorEnergy Infrastructure ( CORR ) +28% . 89bio ( ETNB ) +25% . JanOne ( JAN ) +27% . InMed Phar...

INM - EMAN, LYLT and SOPH among mid-day movers

2023-03-20 13:07:07 ET Gainers: Loyalty Ventures ( LYLT ) +97% . Ambipar Emergency ( AMBI ) +73% . Lifecore Biomedical ( LFCR ) +60% . InMed Pharmaceuticals ( INM ) +43% . New York Community Bancorp ( NYCB ) +32% . Harbor Cus...
Previous 10 Next 10